About
MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine technology for the development, manufacture, and commercialization of vaccines for viruses in humans, starting with COVID-19.
The COVID-19 vaccine project was initiated upon the interdisciplinary research team’s successful development of a vaccine against infectious bronchitis virus (IBV), an avian (poultry) coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following the required genetic adjustments, the same vaccination concepts should apply.
MigVax’s sub-unit vaccine approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This method, based on the IBV vaccine, generates three types of immunological response: mucosal immunity (IgA), blood-based immunity (IgG), and cell-mediated immunity.
Funding history · 3 rounds · $21.3M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was MigVax established and by whom?
- MigVax was established in March 2020 as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license for vaccine technology.
- What is MigVax's primary focus in vaccine development?
- MigVax focuses on developing vaccines for viruses in humans, initially targeting COVID-19, using a sub-unit vaccine approach based on a chimeric protein.
- What was the initial funding round for MigVax?
- In April 2020, MigVax raised $16 million in a Series A round, with OurCrowd and Happiness Capital as investors.
- What type of grant did MigVax receive in November 2021?
- In November 2021, MigVax received a grant of $4.3 million from the IIA.
- What significant partnership did MigVax announce in June 2022?
- In June 2022, MigVax signed an agreement with Catalent to develop an orally disintegrating freeze-dried tablet vaccine against COVID-19.
- Who was appointed as the new CEO of MigVax in May 2022?
- In May 2022, Ran Amir was appointed as the new CEO of MigVax.
- What was MigVax's most recent funding activity according to startupim data?
- MigVax's most recent funding activity was a Convertible Debt round in August 2022, which included investment from OurCrowd.
- How many employees does MigVax currently have?
- MigVax currently has 9 employees.